Previous close | 16.74 |
Open | 17.37 |
Bid | 16.76 x 100 |
Ask | 17.10 x 100 |
Day's range | 16.94 - 17.52 |
52-week range | 8.90 - 38.85 |
Volume | |
Avg. volume | 66,612 |
Market cap | 422.496M |
Beta (5Y monthly) | 1.95 |
PE ratio (TTM) | N/A |
EPS (TTM) | -25.95 |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 23.00 |
Key Insights Cibus' significant individual investors ownership suggests that the key decisions are influenced by...
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on Thursday, May 9, 2024. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updat
Cibus ( NASDAQ:CBUS ) Full Year 2023 Results Key Financial Results Net loss: US$267.6m (loss widened by US$250.7m from...